论文部分内容阅读
蛋白酶体抑制剂是一种新型的肿瘤靶向治疗药物,其通过阻断泛素-蛋白酶体通路,影响细胞内多个短周期蛋白的降解,诱导细胞凋亡,在体内、外均已显示出良好的抗肿瘤效应。研究表明蛋白酶体抑制刺主要通过抑制NF_(-k)B的激活、稳定P_(53)等蛋白的表达等机制促进细胞的凋亡。
Proteasome inhibitor is a new type of tumor targeted therapy that has been shown both in vivo and in vitro by blocking ubiquitin-proteasome pathway, affecting the degradation of multiple short cycle proteins in cells and inducing apoptosis Good anti-tumor effect. Studies have shown that proteasome inhibition mainly through the inhibition of NF _ (- k) B activation, stabilize the expression of P 53 protein and other mechanisms to promote cell apoptosis.